Share This:
Search Results
The DNTP Technical Report (TR) Level of Evidence Criteria are available here: https://ntp.niehs.nih.gov/go/baresults. In the table below this information is further delineated into three fields:
- Level of Evidence: The overall category of evidence of carcinogenic activity for the TR, Species, Strain and Sex
- Organ Site Call: The level of evidence supported by the specific organ site for the TR, Species, Strain and Sex. When the Organ Site Call directly supports the TR Level Of Evidence the Finding Type flag is set to “Neoplastic Lesion”. Some Organ Site Calls could support a separate call of Equivocal Evidence; this is noted in Finding Type by the flag “May Have Been Related”
- Finding Type: Further identification of the Organ Site Call. Where this says “Neoplastic Lesion” the Organ Site Call supports the TR Level of Evidence and the Organ Site Call is the same as that of the TR. Where Finding Type says “May Have Been Related” the TR Level of Evidence for other responses led to an overall call of Clear or Some Evidence but the specified organ supports a call of Equivocal Evidence.
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-028 | 96-12-8 | 1,2-Dibromo-3-chloropropane | Rats | Osborne Mendel | Female | Gavage | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-032 | 3778-73-2 | Isophosphamide | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Mammary Gland | Positive | Positive | (FIBROADENOMA) | Neoplastic Lesions |
| Yes | TR-049 | 7008-42-6 | Acronycine | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-054 | 121-14-2 | 2,4-Dinitrotoluene | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (FIBROADENOMA) | Neoplastic Lesions |
| Yes | TR-055 | 107-06-2 | 1,2-Dichloroethane | Mice | B6C3F1 | Female | Gavage | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-055 | 107-06-2 | 1,2-Dichloroethane | Rats | Osborne Mendel | Female | Gavage | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-060 | 3546-10-9 | Phenesterin | Rats | Sprague Dawley | Female | Gavage | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-092 | 122-66-7 | Hydrazobenzene | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-115 | 95-06-7 | Sulfallate | Mice | B6C3F1 | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-115 | 95-06-7 | Sulfallate | Rats | Osborne Mendel | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-146 | 139-94-6 | Nithiazide | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (FIBROADENOMA OR CYSTADENOMA) | Neoplastic Lesions |
| Yes | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (ADENOMA OR FIBROADENOMA) | Neoplastic Lesions |
| Yes | TR-193 | 50-55-5 | Reserpine | Mice | B6C3F1 | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (FIBROADENOMA, ADENOCARCINOMA, ADENOSQUAMOUS CARCINOMA) | Neoplastic Lesions |
| Yes | TR-162 | 95-80-7 | 2,4-Diaminotoluene (2,4-toluene diamine) | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (ADENOMA, CARCINOMA) | Neoplastic Lesions |
| Yes | TR-207 | 21739-91-3 | Cytembena | Rats | F344/N | Female | Intraperitoneal Injection | Mammary Gland | Positive | Positive | FIBROADENOMA 13/49 22/50 36/50 | Neoplastic Lesions |
| Yes | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Positive | Positive | ADENOCARCINOMA 2/50 14/50 8/50 | Neoplastic Lesions |
| Yes | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Female | Inhalation | Mammary Gland | Positive | Positive | FIBROADENOMA 4/50 29/50 24/50 | Neoplastic Lesions |
| Yes | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Female | Gavage | Mammary Gland | Positive | Positive | FIBROADENOMA 15/50 21/50 18/50 | Neoplastic Lesions |
| Yes | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | ACINAR CELL CARCINOMA 0/50 2/49 6/49 | Neoplastic Lesions |
| Yes | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/49 2/45 5/50 10/49; CARCINOSARCOMA 0/49 0/45 1/50 4/49 | Neoplastic Lesions |
| Yes | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Equivocal Evidence | ADENOMA 0/50 3/50 1/50, FIBROADENOMA 22/50 31/50 29/50, OR ADENOCARCINOMA 2/50 2/50 5/50 COMBINED 23/50 32/50 32/50 | May Have Been Related |
| Yes | TR-306 | 75-09-2 | Methylene chloride | Rats | F344/N | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/50 0/50 1/50 OR FIBROADENOMA 5/50 11/50 13/50 22/50 COMBINED 5/50 11/50 13/50 23/50 | Neoplastic Lesions |
| Yes | TR-306 | 75-09-2 | Methylene chloride | Rats | F344/N | Male | Inhalation | Mammary Gland | Some Evidence | Some Evidence | ADENOMA 0/50 0/50 0/50 1/50 OR FIBROADENOMA 0/50 0/50 2/50 4/50 COMBINED 0/50 0/50 2/50 5/50 | Neoplastic Lesions |
| Yes | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 0/50 5/50 | Neoplastic Lesions |
| Yes | TR-358 | 303-47-9 | Ochratoxin A | Rats | F344/N | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 17/50 23/51 22/50 28/50 | Neoplastic Lesions |
| Yes | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | ADENOACANTHOMA, ADENOCARCINOMA, OR MALIGNANT MIXED TUMOR 0/50 2/50 4/50 12/50 15/50 16/80 | Neoplastic Lesions |
| Yes | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Equivocal Evidence | ADENOCARCINOMA 0/50 3/35 6/65 3/50 | May Have Been Related |
| Yes | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/60 1/45 3/75 6/60 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50 | Neoplastic Lesions |
| Yes | TR-337 | 59-87-0 | Nitrofurazone | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 8/49 36/50 36/50 | Neoplastic Lesions |
| Yes | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 1/50 6/49 12/52 21/52 | Neoplastic Lesions |
| Yes | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 1/60 2/45 14/75 20/60 | Neoplastic Lesions |
| Yes | TR-356 | 54-31-9 | Furosemide | Mice | B6C3F1 | Female | Dosed-Feed | Mammary Gland | Some Evidence | Some Evidence | ADENOCARCINOMA 0/50 2/50 5/48 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 3/50 8/50 7/50 | Neoplastic Lesions |
| Yes | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 1/49 6/48 4/49; ADENOSQUAMOUS CARCINOMA 0/49 2/48 2/49 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50 | Neoplastic Lesions |
| Yes | TR-461 | 75-52-5 | Nitromethane | Rats | F344/N | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 19/50 21/50 33/50 36/50 OR CARCINOMA 2/50 7/50 1/50 11/50 COMBINED 9/50 25/50 34/50 39/50 | Neoplastic Lesions |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 25/50 45/51 46/53 45/52 | Neoplastic Lesions |
| Yes | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Female | Inhalation | Mammary Gland | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 8/50 3/50 2/50 | May Have Been Related |
| Yes | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 24/49 32/50 36/50 36/50 | Neoplastic Lesions |
| Yes | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | CARCINOMA 3/50 4/50 7/50 12/50 | Neoplastic Lesions |
| Yes | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 23/60 47/60 52/60 56/60 | Neoplastic Lesions |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 0/51 4/53 6/51 6/55 5/60 OR ADENOMA 0/51 0/53 1/51 1/55 0/60 COMBINED 0/51 4/53 7/51 7/55 5/60 | Neoplastic Lesions |
| Yes | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 5/50 5/50 15/50 13/50 6/50 | Neoplastic Lesions |
| Yes | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | ADENOACANTHOMA 0/47 1/46 1/46 11/48 ADENOCARCINOMA 4/47 3/46 3/46 11/48 COMBINED 4/47 4/46 4/46 22/48 | Neoplastic Lesions |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Equivocal Evidence | CARCINOMA 0/52 0/50 1/51 2/50 | May Have Been Related |
| Yes | TR-486 | 78-79-5 | Isoprene | Rats | F344/N | Female | Inhalation | Mammary Gland | Some Evidence | Some Evidence | FIBROADENOMA 19/50 35/50 32/50 32/50 MULTIPLE FIBROADENOMA 7/50 12/50 19/50 17/50 | Neoplastic Lesions |
| Yes | TR-486 | 78-79-5 | Isoprene | Rats | F344/N | Male | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 2/50 4/50 6/50 21/50 FIBROADENOMA OR CARCINOMA COMBINED 2/50 5/50 7/50 21/50 | Neoplastic Lesions |
| Yes | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 0/60 7/60 10/60 2/60 13/60 20/60 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ADENOACANTHOMA 0/47 0/45 2/48 3/47 ADENOCARCINOMA 4/47 3/45 11/48 14/47 COMBINED 4/47 3/45 12/48 16/47 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ADENOACANTHOMA 0/47 0/48 1/48 9/45 ADENOCARCINOMA 3/47 4/48 6/48 15/45 COMBINED 3/47 4/48 7/48 23/45 | Neoplastic Lesions |
| Yes | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | fibroadenoma 16/48 26/48 35/48 33/48 36/48 | Neoplastic Lesions |
| Yes | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | fibroadenoma 16/48 18/48 24/46 22/47 31/48 | Neoplastic Lesions |
| Yes | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | adenoacanthoma 0/47 1/46 1/48 2/45 4/42 adenocarcinoma 0/47 4/46 6/48 2/45 13/42 adenoacanthoma or adenocarcinoma 0/47 4/46 7/48 4/45 17/42 | Neoplastic Lesions |
| Yes | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | adenoacanthoma 0/45 0/48 0/47 1/47 8/45 adenocarcinoma 1/45 1/48 2/47 9/47 11/45 adenoacanthoma or adenocarcinoma 1/45 1/48 2/47 9/47 18/45 | Neoplastic Lesions |
| Yes | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | fibroadenoma 28/50 47/50 47/50 39/50 carcinoma 0/50 1/50 3/50 8/50 fibroadenoma, adenoma, or carcinoma 28/50 47/50 48/50 42/50 | Neoplastic Lesions |
| Yes | TR-545 | 446-72-0 | Endocrine disruptor (Genistein) | Rats | Sprague Dawley | Female | Dosed-Feed | Mammary Gland | Some Evidence | Equivocal Evidence | ADENOMA OR ADENOCARCINOMA 7/53 8/49 11/50 13/50 | May Have Been Related |
| Yes | TR-545 | 446-72-0 | Endocrine disruptor (Genistein) | Rats | Sprague Dawley | Female | Dosed-Feed | Mammary Gland | Some Evidence | Some Evidence | ADENOMA OR ADENOCARCINOMA 9/54 4/50 8/50 16/49 | Neoplastic Lesions |
| Yes | TR-549 | 5589-96-8 | Water disinfection byproducts (Bromochloroacetic acid) | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | Fibroadenoma, multiple 22/50 24/50 43/50 38/50 | Neoplastic Lesions |
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | TR-028 | 96-12-8 | 1,2-Dibromo-3-chloropropane | Mice | B6C3F1 | Female | Gavage | Forestomach | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| No | TR-028 | 96-12-8 | 1,2-Dibromo-3-chloropropane | Mice | B6C3F1 | Male | Gavage | Forestomach | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| No | TR-028 | 96-12-8 | 1,2-Dibromo-3-chloropropane | Rats | Osborne Mendel | Female | Gavage | Forestomach | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| No | TR-028 | 96-12-8 | 1,2-Dibromo-3-chloropropane | Rats | Osborne Mendel | Male | Gavage | Forestomach | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| Yes | TR-028 | 96-12-8 | 1,2-Dibromo-3-chloropropane | Rats | Osborne Mendel | Female | Gavage | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Female | Inhalation | Lung | Positive | Positive | ALVEOLAR/BRONCHIOLAR ADENOMA 3/49 7/49 13/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/49 5/49 37/50 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Male | Inhalation | Lung | Positive | Positive | ALVEOLAR/BRONCHIOLAR ADENOMA 0/41 0/48 11/46; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/41 3/48 19/46 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Female | Inhalation | Lung | Positive | Positive | ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 0/48 1/47 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/48 4/47 COMBINED 0/50 0/48 5/47 | Neoplastic Lesions |
| Yes | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Positive | Positive | ADENOCARCINOMA 2/50 14/50 8/50 | Neoplastic Lesions |
| Yes | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Female | Inhalation | Mammary Gland | Positive | Positive | FIBROADENOMA 4/50 29/50 24/50 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Male | Inhalation | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | MESOTHELIOMA 0/50 7/50 25/50 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Female | Inhalation | Nasal Cavity | Positive | Positive | CARCINOMA 0/50 0/50 6/50 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Female | Inhalation | Nasal Cavity | Positive | Positive | ADENOMA 0/50 11/50 3/50; ADENOCARCINOMA 0/50 20/50 29/50; CARCINOMA 0/50 0/50 25/50 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Male | Inhalation | Nasal Cavity | Positive | Positive | ADENOMA 0/50 11/50 0/50; ADENOCARCINOMA 0/50 20/50 28/50; CARCINOMA 0/50 0/50 21/50 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Female | Inhalation | Subcutaneous Tissue | Positive | Positive | FIBROSARCOMA 0/50 5/50 11/50 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Mice | B6C3F1 | Female | Inhalation | Vascular System (Unspecified) | Positive | Positive | HEMANGIOSARCOMA 0/50 11/50 23/50 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Female | Inhalation | Vascular System (Unspecified) | Positive | Positive | HEMANGIOSARCOMA 0/50 0/50 5/50 | Neoplastic Lesions |
| No | TR-210 | 106-93-4 | 1,2-Dibromoethane | Rats | F344/N | Male | Inhalation | Vascular System (Unspecified) | Positive | Positive | HEMANGIOSARCOMA 0/50 1/50 15/50 | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Rats | Osborne Mendel | Male | Gavage | Forestomach | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Mice | B6C3F1 | Female | Gavage | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA) | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Mice | B6C3F1 | Male | Gavage | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA) | Neoplastic Lesions |
| Yes | TR-055 | 107-06-2 | 1,2-Dichloroethane | Mice | B6C3F1 | Female | Gavage | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-055 | 107-06-2 | 1,2-Dichloroethane | Rats | Osborne Mendel | Female | Gavage | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Rats | Osborne Mendel | Male | Gavage | Subcutaneous Tissue | Positive | Positive | (FIBROMA) | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Positive | Positive | (POLYP, SARCOMA) | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Rats | Osborne Mendel | Male | Gavage | Vascular System (Unspecified) | Positive | Positive | (HEMANGIOSARCOMA) | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/46 10/46 13/50 10/51 OR CARCINOMA 0/46 0/46 4/50 6/51 COMBINED 5/46 10/46 17/50 15/51 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 23/50 18/51 29/55; SQUAMOUS CELL CARCINOMA 0/50 46/50 49/51 49/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 3/52 28/51 22/54 33/56; SQUAMOUS CELL CARCINOMA 0/52 40/51 50/54 51/56 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 13/49 32/51 17/52; SQUAMOUS CELL CARCINOMA 0/50 3/49 9/51 4/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 29/50 33/49 38/52; SQUAMOUS CELL CARCINOMA 0/50 9/50 27/49 13/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/50 6/50 7/51 10/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 1/52 2/51 10/54 11/56 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Intestines (Large) | Clear Evidence | Equivocal Evidence | ADENOCARCINOMA 0/49 0/47 1/52 2/52 | May Have Been Related |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Intestines (Large) | Clear Evidence | Equivocal Evidence | ADENOCARCINOMA 0/50 0/50 2/48 1/52 | May Have Been Related |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/50 20/49 21/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 6/50 9/50 8/51 31/55 OR CARCINOMA 1/50 3/50 0/51 2/55 COMBINED 7/50 11/50 8/51 31/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 11/52 18/51 21/54 29/56; CARCINOMA 13/52 24/51 24/54 31/56 | Neoplastic Lesions |
| Yes | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 1/50 6/49 12/52 21/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Oral Cavity | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/52 0/51 0/54 2/56 | May Have Been Related |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/50 0/50 1/51 5/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 5/49 10/52 18/52 ; SQUAMOUS CELL CARCINOMA 0/50 1/49 21/52 21/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 4/50 9/49 19/52; SQUAMOUS CELL CARCINOMA 1/50 0/50 11/49 25/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Pancreas Acinar Cell | Clear Evidence | Clear Evidence | ADENOMA 5/50 21/50 36/49 29/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 5/49 3/47 5/49 11/50 OR CARCINOMA 0/49 3/47 3/49 5/50 COMBINED 5/49 6/47 8/49 16/50 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/51 3/54; ADENOCARCINOMA 0/50 4/50 3/51 6/54; POLYP 0/50 2/50 1/51 6/54 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/60 1/59 0/60 4/60 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/60 0/60 0/59 3/60 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Brain | Clear Evidence | Equivocal Evidence | GLIOMA 0/50 2/48 1/49 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Brain | Clear Evidence | Clear Evidence | (STOP STUDY) GLIOMA 0/50 2/50 0/50 1/50 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Forestomach | Clear Evidence | Clear Evidence | PAPILLOMA 0/49 4/42 10/49 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 3/50 2/50 4/50 22/80 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Forestomach | Clear Evidence | Clear Evidence | PAPILLOMA 0/49 5/40 0/44 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR CARCINOMA 1/50 0/50 0/50 1/50 8/50 4/73, STOP STUDY 3/50 7/50 9/50 10/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 8/50 10/50 7/50 15/50 20/50 9/80 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 6/50 7/50 9/50 20/50 31/50 6/73, STOP STUDY 27/50 23/50 30/50 13/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 6/50 12/50 11/50 7/50 9/50 32/80; HISTIOCYTIC SARCOMA 3/50 2/50 7/50 4/50 7/50 4/80 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 1/50 10/49 10/49 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 0/50 23/50 29/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 4/50 2/50 4/50 6/50 2/50 51/73, STOP STUDY 8/50 22/50 8/50 33/50; HISTIOCYTIC SARCOMA 0/50 0/50 4/50 5/50 7/50 4/73, STOP STUDY 5/50 2/50 7/50 2/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Intestines (Small) | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 1/50 1/50 1/50 2/50 0/73 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Kidney Tubular Cell | Clear Evidence | Equivocal Evidence | ADENOMA 0/49 0/49 0/48 0/50 2/50 0/80 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/50 3/48 1/49 0/73, STOP STUDY 4/48 1/50 3/49 1/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 15/49 14/49 15/50 19/50 16/50 2/80 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/47 4/49 OR CARCINOMA 0/50 1/47 1/49 COMBINED 0/50 2/47 5/49 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 21/50 23/50 30/50 25/48 33/48 5/72, STOP STUDY 27/49 19/49 19/50 11/50 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 3/49 9/48 20/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/49 6/48 8/49 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 4/50 15/50 19/50 24/50 25/50 22/78 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 2/50 12/49 11/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 2/49 5/49 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 21/50 23/50 19/50 31/49 35/50 3/73, STOP STUDY 36/50 28/50 32/50 17/50 | Neoplastic Lesions |
| Yes | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | ACINAR CELL CARCINOMA 0/50 2/49 6/49 | Neoplastic Lesions |
| Yes | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | ADENOACANTHOMA, ADENOCARCINOMA, OR MALIGNANT MIXED TUMOR 0/50 2/50 4/50 12/50 15/50 16/80 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Ovary | Clear Evidence | Clear Evidence | BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 1/49 0/49 1/48 9/50 8/50 6/79; ADENOMA OR BENIGN MIXED TUMOR 2/49 4/49 1/48 4/50 6/50 2/79 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Ovary | Clear Evidence | Clear Evidence | GRANULOSA CELL TUMOR 0/49 6/45 12/48 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Preputial Gland | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL CARCINOMA 0/50 3/50 1/50 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Preputial Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/50 0/50 0/50 0/50 5/50 0/73, STOP STUDY 1/50 4/50 4/50 3/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Subcutaneous Tissue | Clear Evidence | Equivocal Evidence | NEUROFIBROSARCOMA OR SARCOMA 1/50 2/50 3/50 5/50 3/50 3/80 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Vascular System (Heart) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 0/50 0/50 1/49 21/50 23/80 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Vascular System (Heart) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 11/48 18/49 | Neoplastic Lesions |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Vascular System (Heart) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 16/49 7/49 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Vascular System (Heart) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 0/49 1/50 5/48 20/48 4/73, STOP STUDY 15/50 7/50 33/50 13/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Zymbal Gland | Clear Evidence | Equivocal Evidence | ADENOMA OR CARCINOMA 0/50 0/50 0/50 0/50 0/50 2/80 | May Have Been Related |
| No | TR-288 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Zymbal Gland | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 0/50 2/50 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Zymbal Gland | Clear Evidence | Equivocal Evidence | (STOP STUDY) CARCINOMA 1/50 0/50 2/50 2/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/51 1/53 10/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 0/53 1/51 5/55 0/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/52 1/50 5/51 3/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/50 3/51 2/50 2/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/51 1/50 2/49 COMBINED 0/50 3/51 3/50 4/49 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 0/53 0/51 1/55 5/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/52 6/50 8/51 15/50 OR CARCINOMA 1/52 6/50 5/51 7/50 COMBINED 3/52 12/50 13/51 19/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/50 6/51 12/50 18/49 OR CARCINOMA 1/50 1/51 4/50 4/49 COMBINED 4/50 7/51 16/50 22/49 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 27/51 29/53 40/51 34/55 25/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 0/51 0/53 3/51 4/55 11/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Intestines (Small) | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 0/51 0/53 0/51 2/53 5/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Equivocal Evidence | ADENOMA 0/51 0/53 1/51 3/55 1/59 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/51 3/50 2/49 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 3/52 3/50 9/51 17/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/52 2/50 6/51 5/50 COMBINED 5/52 5/50 15/51 19/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 12/50 4/51 12/50 21/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 7/51 8/50 11/49 COMBINED 15/50 11/51 16/50 25/49 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/51 0/53 3/51 1/55 4/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 1/53 0/51 3/55 3/60 COMBINED 1/51 1/53 3/51 4/55 7/60 | Neoplastic Lesions |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Equivocal Evidence | CARCINOMA 0/52 0/50 1/51 2/50 | May Have Been Related |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 25/50 45/51 46/53 45/52 | Neoplastic Lesions |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 0/51 4/53 6/51 6/55 5/60 OR ADENOMA 0/51 0/53 1/51 1/55 0/60 COMBINED 0/51 4/53 7/51 7/55 5/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 0/51 3/53 8/51 9/55 26/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/50 2/51 4/53 5/52 OR SQUAMOUS CELL CARCINOMA 0/50 1/51 1/53 1/52 COMBINED 2/50 3/51 5/53 6/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 4/53 8/51 10/55 12/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 1/51 0/55 2/60 COMBINED 0/51 4/53 9/51 10/55 13/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | Equivocal Evidence | ADENOMA 1/51 2/53 4/51 3/53 3/59 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Seminal Vesicle | Clear Evidence | Clear Evidence | ADENOMA 0/51 0/53 0/51 0/55 1/59 OR CARCINOMA 0/51 0/53 0/51 0/55 1/59 COMBINED 0/51 0/53 0/51 0/55 2/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/51 0/53 2/51 5/55 11/60 OR KERATOACANTHOMA 3/51 5/53 11/51 16/55 10/60 OR TRICHOEPITHELIOMA 0/51 0/53 0/51 1/55 1/60 OR BASAL CELL ADENOMA 0/51 1/53 0/51 3/55 6/60 OR BASAL CELL CARCINOMA 0/51 0/53 2/51 2/55 0/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 0/51 0/55 1/60 COMBINED 4/51 6/53 14/51 24/55 21/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/52 1/50 4/51 11/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | FIBROMA 2/51 8/53 11/51 15/55 7/60 OR FIBROSARCOMA 0/51 1/53 0/51 0/55 1/60 OR SARCOMA 0/51 0/53 2/51 3/55 2/60 COMBINED 2/51 9/53 13/51 16/55 10/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/51 2/53 3/52 OR CARCINOMA 0/50 0/51 0/53 1/52 COMBINED 0/50 0/51 2/53 4/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/51 1/53 2/51 2/55 7/59 OR CARCINOMA 0/51 1/53 4/51 1/55 2/59 COMBINED 0/51 2/53 6/51 3/55 9/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Urinary Bladder | Clear Evidence | Clear Evidence | TRANSITIONAL CELL PAPILLOMA 0/51 0/53 1/51 2/55 1/59 OR TRANSITIONAL CELL CARCINOMA 0/51 0/53 0/51 1/55 1/59 COMBINED 0/51 0/53 1/51 3/55 2/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Vascular System (Unspecified) | Clear Evidence | Equivocal Evidence | HEMANGIOMA AND HEMANGIOSARCOMA 1/52 2/50 0/51 5/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/51 0/53 1/51 3/55 2/60 OR CARCINOMA 2/51 1/53 3/51 2/55 15/60 COMBINED 2/51 1/53 4/51 5/55 15/60 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 3/50 OR ADENOCARCINOMA 0/50 0/50 3/50 COMBINED 0/50 1/50 6/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 9/50 38/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 19/50 33/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Female | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 12/49 17/50 OR SQUAMOUS CELL CARCINOMA 0/50 7/47 6/50 COMBINED 0/50 18/49 19/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 12/50 20/50 OR SQUAMOUS CELL CARCINOMA 0/50 2/50 1/49 COMBINED 0/50 14/50 21/49 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 23/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 17/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 3/50 4/49; ADENOMATOUS POLYP 0/50 12/50 37/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 8/50 11/50; ADENOMATOUS POLYP 1/50 13/50 29/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 4/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Liver | Clear Evidence | Clear Evidence | ADENOMA 1/50 2/50 9/50 OR CARCINOMA 0/50 0/50 3/50 COMBINED 1/50 2/50 11/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULES 0/50 10/50 11/50 OR CARCINOMA 0/50 2/50 6/50 COMBINED 0/50 11/50 14/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULES 0/49 3/50 2/50 OR CARCINOMA 0/49 1/50 3/50 COMBINED 0/49 4/50 5/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Female | Topical Application | Lung | Clear Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 3/50 4/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 0/50 0/50 COMBINED 1/50 3/50 4/50 | May Have Been Related |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 1/50 6/50 | Neoplastic Lesions |
| Yes | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 0/50 5/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | 0/50 1/50 4/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Nasal Cavity | Clear Evidence | Clear Evidence | ADENOMA 0/50 44/50 49/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Nasal Cavity | Clear Evidence | Clear Evidence | ADENOMA 0/50 48/50 48/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 27/50 41/50 OR SQUAMOUS CELL CARCINOMA 0/50 15/50 27/50 COMBINED 0/50 39/50 49/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 40/50 33/50 OR SQUAMOUS CELL CARCINOMA 0/50 16/50 25/50 COMBINED 0/50 47/50 48/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Female | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 1/50 6/50; SEBACEOUS GLAND ADENOMA 0/50 3/50 2/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 3/50 9/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 2/50 COMBINED 0/50 3/50 11/50; SEBACEOUS GLAND ADENOMA 0/50 1/50 8/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 3/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA OR KERATOACANTHOMA 0/50 3/50 18/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 0/50 OR SQUAMOUS CELL CARCINOMA 0/50 5/50 8/50 COMBINED 1/50 8/50 8/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA, OR KERATOACANTHOMA 0/50 20/50 31/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Vascular System (Spleen) | Clear Evidence | Clear Evidence | HEMANGIOMA 0/50 0/50 3/50 OR HEMANGIOSARCOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 7/50 3/50 OR ADENOCARCINOMA 1/50 2/50 19/50 COMBINED 1/50 9/50 22/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 7/50 OR ADENOCARCINOMA 0/50 8/50 29/50 COMBINED 0/50 9/50 35/50 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Mice | B6C3F1 | Male | Gavage | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Mice | B6C3F1 | Female | Gavage | Liver | Positive | Positive | ADENOMA 2/50 3/50 12/50 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Female | Gavage | Liver | Positive | Positive | NEOPLASTIC NODULE 3/50 8/50 8/48 | Neoplastic Lesions |
| Yes | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Female | Gavage | Mammary Gland | Positive | Positive | FIBROADENOMA 15/50 21/50 18/50 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Male | Gavage | Pancreas Acinar Cell | Positive | Positive | ADENOMA 1/47 3/47 7/49 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Female | Gavage | Pancreas Islet Cell | Positive | Positive | ADENOMA 0/50 6/49 2/47 CARCINOMA 0/50 1/49 0/47 COMBINED 0/50 7/49 2/47 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Female | Gavage | Subcutaneous Tissue | Positive | Positive | FIBROMA 0/50 1/50 3/50 OR FIBROSARCOMA 2/50 0/50 2/50 COMBINED 2/50 1/50 5/50 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Rats | F344/N | Male | Gavage | Subcutaneous Tissue | Positive | Positive | FIBROMA 3/50 3/50 9/50 OR FIBROSARCOMA 0/50 3/50 3/50 COMBINED 3/50 6/50 12/50 | Neoplastic Lesions |
| No | TR-251 | 26471-62-5 | 2,4- & 2,6-Toluene diisocyanate | Mice | B6C3F1 | Female | Gavage | Vascular System (Unspecified) | Positive | Positive | HEMANGIOMA 0/50 1/50 2/50 OR HEMANGIOSARCOMA 0/50 0/50 3/50 COMBINED 0/50 1/50 5/50 | Neoplastic Lesions |
| No | TR-162 | 95-80-7 | 2,4-Diaminotoluene (2,4-toluene diamine) | Mice | B6C3F1 | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-162 | 95-80-7 | 2,4-Diaminotoluene (2,4-toluene diamine) | Mice | B6C3F1 | Female | Dosed-Feed | Hematopoietic System | Positive | Equivocal Evidence | (LYMPHOMA) | May Have Been Related |
| No | TR-162 | 95-80-7 | 2,4-Diaminotoluene (2,4-toluene diamine) | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-162 | 95-80-7 | 2,4-Diaminotoluene (2,4-toluene diamine) | Rats | F344/N | Female | Dosed-Feed | Liver | Positive | Positive | (NEOPLASTIC NODULE, CARCINOMA) | Neoplastic Lesions |
| No | TR-162 | 95-80-7 | 2,4-Diaminotoluene (2,4-toluene diamine) | Rats | F344/N | Male | Dosed-Feed | Liver | Positive | Positive | (NEOPLASTIC NODULE, CARCINOMA) | Neoplastic Lesions |
| Yes | TR-162 | 95-80-7 | 2,4-Diaminotoluene (2,4-toluene diamine) | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (ADENOMA, CARCINOMA) | Neoplastic Lesions |
| No | TR-054 | 121-14-2 | 2,4-Dinitrotoluene | Mice | B6C3F1 | Female | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-054 | 121-14-2 | 2,4-Dinitrotoluene | Mice | B6C3F1 | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| Yes | TR-054 | 121-14-2 | 2,4-Dinitrotoluene | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (FIBROADENOMA) | Neoplastic Lesions |
| No | TR-054 | 121-14-2 | 2,4-Dinitrotoluene | Rats | F344/N | Male | Dosed-Feed | Skin | Positive | Positive | (FIBROMA) | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/60 2/44 3/75 1/60 | May Have Been Related |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/58 15/44 13/74 16/55; CARCINOMA 2/58 17/44 41/74 30/55 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 0/45 1/75 2/60 OR ADENOCARCINOMA 0/60 1/45 0/75 1/60 COMBINED 0/60 1/45 1/75 3/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 1/45 4/75 5/60 OR ADENOCARCINOMA 0/60 4/45 11/75 8/60 COMBINED 0/60 4/45 14/75 13/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 1/44 0/75 2/60 OR CARCINOMA 0/60 0/44 0/75 1/60 COMBINED 0/60 1/44 0/75 3/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 3/45 7/74 6/60; NEOPLASTIC NODULE OR CARCINOMA 1/60 1/45 0/74 2/60 COMBINED 1/60 4/45 7/74 8/60 | Neoplastic Lesions |
| Yes | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 1/60 2/45 14/75 20/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 2/60 1/45 7/75 6/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/60 2/45 3/75 3/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 3/75 2/60 COMBINED 2/60 2/45 6/75 5/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/60 7/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/60 1/45 0/75 2/60 COMBINED 1/60 8/45 10/75 11/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 14/60 6/43 19/73 12/59 OR CARCINOMA 2/60 6/43 15/73 19/59 COMBINED 16/60 12/43 33/73 29/59 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 0/60; BASAL CELL NEOPLASMS 0/60 4/45 3/75 2/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL OR SEBACEOUS GLAND NEOPLASMS 2/60 33/45 56/75 41/60; SQUAMOUS CELL NEOPLASMS 0/60 13/45 28/75 22/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/60 3/45 1/75 2/59 OR CARCINOMA 0/60 1/45 1/75 0/59 COMBINED 0/60 4/45 2/75 2/59 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/60 3/45 4/75 3/60 OR CARCINOMA 1/60 10/45 17/75 13/60 COMBINED 1/60 12/45 21/75 16/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/59 4/45 11/75 9/60; CARCINOMA 0/59 7/45 14/75 21/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/60 1/45 1/75 0/60; GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 1/45 0/75 0/60 | May Have Been Related |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 0/45 0/75 1/60; MENINGEAL SARCOMA 0/60 0/45 1/75 0/60 | May Have Been Related |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 0/60 9/45 32/75 17/59 OR CARCINOMA 0/60 5/45 11/75 18/59 COMBINED 0/60 14/45 42/75 32/59 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 1/60 3/45 6/75 4/60 | May Have Been Related |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 2/45 7/75 4/60 OR ADENOCARCINOMA 0/60 0/45 3/75 6/60 COMBINED 0/60 2/45 10/75 9/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 0/45 7/75 10/60 OR ADENOCARCINOMA 0/60 0/45 3/75 15/60 COMBINED 0/60 0/45 10/75 23/75 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 0/45 7/74 3/60 OR CARCINOMA 0/60 0/45 1/74 1/60 COMBINED 0/60 0/45 7/74 4/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 0/45 29/75 26/60 OR CARCINOMA 0/60 0/45 12/75 12/60 COMBINED 0/60 0/45 35/75 33/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 1/45 3/74 3/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/60 0/45 0/74 1/60 COMBINED 1/60 1/45 3/74 4/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 0/45 7/75 6/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/60 0/45 1/75 0/60 COMBINED 1/60 0/45 8/75 6/60 | Neoplastic Lesions |
| Yes | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/60 1/45 3/75 6/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 0/60 0/45 3/75 4/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/60 3/45 7/75 9/60 OR SQUAMOUS CELL CARCINOMA 0/60 1/45 2/75 4/60 COMBINED 0/60 3/45 9/75 13/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 2/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 1/75 3/60 COMBINED 0/60 0/45 4/75 5/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 2/60 4/45 4/75 8/60 OR CARCINOMA 0/60 0/45 2/75 1/60 COMBINED 2/60 4/45 6/75 9/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 0/60 3/45 5/75 5/60 OR BASAL CELL CARCINOMA 0/60 0/45 5/75 4/60 COMBINED 0/60 3/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA 0/60 1/45 6/75 5/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 4/75 7/60 COMBINED 0/60 3/45 9/75 12/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 0/60 10/45 52/75 29/60 OR BASAL CELL CARCINOMA 0/60 1/45 4/75 2/60 COMBINED 0/60 11/45 54/75 30/60; SEBACEOUS GLAND ADENOMA 0/60 0/45 7/75 5/60; KERATOACANTHOMA 1/60 1/45 8/75 5/60; SQUAMOUS CELL PAPILLOMA 0/60 0/45 8/75 15/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 10/75 13/60 COMBINED 0/60 2/45 17/75 27/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/60 4/45 11/75 12/60 OR CARCINOMA 0/60 2/45 22/75 35/60 COMBINED 0/57 6/45 32/75 42/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 1/60 1/45 13/75 16/60 OR CARCINOMA 0/60 2/45 21/75 23/60 COMBINED 1/60 3/45 32/75 36/60 | Neoplastic Lesions |
| No | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Mice | B6C3F1 | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Rats | F344/N | Female | Dosed-Feed | Clitoral Gland | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Rats | F344/N | Female | Dosed-Feed | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| No | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Rats | F344/N | Male | Dosed-Feed | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| Yes | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Mice | B6C3F1 | Female | Dosed-Feed | Ovary | Positive | Positive | (TUBULAR CELL ADENOMA OR GRANULOSA CELL TUMOR OR LUTEOMA) | Neoplastic Lesions |
| No | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Rats | F344/N | Female | Dosed-Feed | Zymbal Gland | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-049 | 7008-42-6 | Acronycine | Mice | B6C3F1 | Female | Intraperitoneal Injection | Unspecified | Inadequate Study | Not applicable | Not applicable | |
| No | TR-049 | 7008-42-6 | Acronycine | Mice | B6C3F1 | Male | Intraperitoneal Injection | Unspecified | Inadequate Study | Not applicable | Not applicable | |
| No | TR-049 | 7008-42-6 | Acronycine | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Bone | Positive | Positive | (OSTEOSARCOMA) | Neoplastic Lesions |
| Yes | TR-049 | 7008-42-6 | Acronycine | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-049 | 7008-42-6 | Acronycine | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | MESOTHELIOMA; SARCOMA | Neoplastic Lesions |
| No | TR-049 | 7008-42-6 | Acronycine | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | MESOTHELIOMA; SARCOMA | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | carcinoma 1/4 6/48 12/47 3/48 8/47 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Epididymis | Clear Evidence | Clear Evidence | malignant mesothelioma 2/48 2/48 1/48 5/48 8/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Epididymis or Testis | Clear Evidence | Clear Evidence | malignant mesothelioma 2/48 2/48 1/48 5/48 8/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 4/46 0/46 2/48 5/45 8/42 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Male | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 0/46 2/45 2/46 6/47 6/44 squamous cell carcinoma 0/46 0/45 0/46 1/47 2/44 squamous cell papilloma or carcinoma 0/46 2/45 2/46 7/47 8/44 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 0/45 8/44 20/48 32/47 31/43 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 2/46 13/46 27/47 36/47 39/47 adenocarcinoma 0/46 0/46 0/47 1/47 1/47 adenoma or adenocarcinoma 2/46 13/46 27/47 37/47 39/47 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Heart | Clear Evidence | Clear Evidence | malignant Schwannoma 2/48 1/48 0/48 2/48 4/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | malignant Schwannoma 1/48 2/48 3/48 4/48 6/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | adenoma 0/48 0/48 1/48 1/48 3/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 1/47 4/47 6/48 11/45 19/45 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 5/47 6/46 13/47 10/45 19/48 alveolar/bronchiolar adenoma or carcinoma 6/47 6/46 14/47 10/45 20/48 | Neoplastic Lesions |
| Yes | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | adenoacanthoma 0/47 1/46 1/48 2/45 4/42 adenocarcinoma 0/47 4/46 6/48 2/45 13/42 adenoacanthoma or adenocarcinoma 0/47 4/46 7/48 4/45 17/42 | Neoplastic Lesions |
| Yes | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | fibroadenoma 16/48 18/48 24/46 22/47 31/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | squamous cell papilloma or carcinoma 0/48 2/48 1/48 3/48 5/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Ovary | Clear Evidence | Clear Evidence | benign granulose cell tumor 0/46 1/45 0/48 1/45 5/42 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Pancreas Islet Cell | Clear Evidence | Clear Evidence | adenoma 1/46 2/48 4/48 1/48 6/48 carcinoma 0/46 0/48 0/48 1/48 0/48 adenoma or carcinoma 1/46 2/48 4/48 2/48 6/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | fibrosarcoma, fibrous histocytoma, myxosarcoma, neurofibrosarcoma, or sarcoma 0/48 0/46 3/48 10/45 6/43 squamous cell carcinoma 0/48 0/46 0/48 0/45 2/43 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | subcutaneous tissue fibroma, fibrosarcoma or sarcoma 1/48 0/48 0/48 1/48 5/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Testis | Clear Evidence | Clear Evidence | malignant mesothelioma 1/48 2/48 1/48 1/48 5/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 0/48 0/48 1/48 0/48 2/47 carcinoma 0/48 0/48 1/48 3/48 2/47 adenoma or carcinoma 0/48 0/48 2/48 3/48 4/47 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 0/47 1/48 1/47 1/48 3/48 carcinoma 1/47 2/48 3/47 6/48 6/48 l adenoma or carcinoma 1/47 3/48 4/47 6/48 9/48 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 0/49 9/46 13/49 11/48 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Female | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 15/49 25/45 26/50 22/49 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Male | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 4/49 10/48 10/50 15/49 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Female | Gavage | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 4/49 2/42 5/50 9/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/49 3/42 6/50 6/49 COMBINED 4/49 5/42 10/50 13/49 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Male | Gavage | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 6/49 6/48 8/50 12/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 5/49 11/48 12/50 14/49 COMBINED 10/49 16/48 19/50 21/49 | Neoplastic Lesions |
| Yes | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/49 2/45 5/50 10/49; CARCINOSARCOMA 0/49 0/45 1/50 4/49 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Rats | F344/N | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 4/50 8/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 1/50 4/50 5/50 COMBINED 1/50 5/50 12/50 9/50 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Rats | F344/N | Male | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 6/50 11/50 13/50 OR SQUAMOUS CELL CARCINOMA 0/50 3/50 5/50 7/50 COMBINED 1/50 9/50 16/50 19/50 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Female | Gavage | Ovary | Clear Evidence | Clear Evidence | BENIGN MIXED TUMORS 0/47 1/44 12/49 7/48; GRANULOSA CELL TUMOR 1/47 1/44 6/49 7/48 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Male | Gavage | Preputial Gland | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/21 3/28 18/29 28/35 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Rats | F344/N | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/50 1/50 5/50; SQUAMOUS CELL CARCINOMA 0/50 5/50 3/50 8/50 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Female | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/43 0/32 1/37 3/31 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/43 1/34 4/40 21/39 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Rats | F344/N | Female | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/45 5/40 5/44 14/46 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Rats | F344/N | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 2/32 6/46 10/42 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Adrenal Gland Medulla | Clear Evidence | Equivocal Evidence | PHEOCHROMOCYTOMA 1/50 3/35 5/64 1/50 | May Have Been Related |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Adrenal Gland Medulla | Clear Evidence | Equivocal Evidence | PHEOCHROMOCYTOMA 16/50 11/35 24/63 19/49 OR MALIGNANT PHEOCHROMOCYTOMA 2/50 0/35 3/63 2/49 COMBINED 17/50 11/35 27/63 21/49 | May Have Been Related |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 7/48 10/32 10/62 10/50, CARCINOMA 4/48 9/32 19/62 15/50, COMBINED 11/48 17/32 28/62 23/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 12/50 13/35 18/65 5/50 | May Have Been Related |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 1/35 0/65 3/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 0/35 1/65 2/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/50 0/35 15/64 6/50, CARCINOMA 0/50 0/35 6/64 3/50, COMBINED 0/50 0/35 19/64 8/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 2/50 1/35 10/65 15/50, CARCINOMA 0/50 1/35 6/65 7/50, COMBINED 2/50 2/35 15/65 20/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Lung | Clear Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 2/35 1/65 3/50, ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 2/50 2/35 2/65 3/50 | May Have Been Related |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 2/35 8/65 4/50, ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 1/50 2/35 9/65 4/50 | Neoplastic Lesions |
| Yes | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Equivocal Evidence | ADENOCARCINOMA 0/50 3/35 6/65 3/50 | May Have Been Related |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/35 1/65 2/50 | May Have Been Related |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 3/35 6/65 4/50, SQUAMOUS CELL CARCINOMA 0/50 0/35 3/65 2/50, COMBINED 0/50 3/35 9/65 6/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 0/50 3/35 5/65 3/50, BASAL CELL CARCINOMA 0/50 1/35 2/65 2/50, COMBINED 0/50 4/35 7/65 5/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 1/50 4/35 26/65 30/50, BASAL CELL CARCINOMA 0/50 1/35 5/65 6/50, COMBINED 1/50 5/35 28/65 32/50; KERATOACANTHOMA 1/50 1/35 4/65 7/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 5/65 5/50, SEBACEOUS GLAND CARCINOMA 1/50 0/35 0/65 1/50, COMBINED 1/50 1/35 5/65 6/50; SQUAMOUS CELL PAPILLOMA 1/50 0/35 3/65 2/50, SQUAMOUS CELL CARCINOMA 0/50 2/35 8/65 7/50, COMBINED 1/50 2/35 11/65 9/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/35 2/65 6/50, CARCINOMA 0/50 3/35 17/65 13/50, COMBINED 0/50 3/35 18/65 19/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/35 1/65 1/50, CARCINOMA 0/50 0/35 7/65 6/50, COMBINED 0/50 0/35 8/65 7/50 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Mice | B6C3F1 | Female | Dosed-Feed | Adrenal Gland Medulla | Clear Evidence | Clear Evidence | PHEOCHROMOCYTOMA 1/48 7/47 7/45 OR MALIGNANT PHEOCHROMOCYTOMA 0/48 1/47 1/45 COMBINED 1/48 8/47 8/45 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Mice | B6C3F1 | Female | Dosed-Feed | Hematopoietic System | Clear Evidence | Equivocal Evidence | LYMPHOMA 17/50 24/50 25/50 | May Have Been Related |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | CARCINOMA 3/49 19/50 37/49 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Mice | B6C3F1 | Male | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | CARCINOMA 10/50 20/50 27/50 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Male | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | CARCINOMA 0/50 2/50 8/50 | Neoplastic Lesions |
| Yes | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Equivocal Evidence | ADENOMA 0/50 3/50 1/50, FIBROADENOMA 22/50 31/50 29/50, OR ADENOCARCINOMA 2/50 2/50 5/50 COMBINED 23/50 32/50 32/50 | May Have Been Related |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Male | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | TRICHOEPITHELIOMA 0/50 0/50 7/50; SEBACEOUS ADENOMA 0/50 0/50 5/50; SQUAMOUS CELL CARCINOMA 0/50 1/50 10/50 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Female | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | FIBROMA 0/50 15/50 10/50 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Male | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | FIBROMA 2/50 20/50 16/50 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Female | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/47 0/48 4/50 OR CARCINOMA 0/47 2/48 2/50 COMBINED 0/47 2/48 6/50 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/49 0/46 9/44 OR CARCINOMA 0/49 5/46 18/44 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Female | Dosed-Feed | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/50 2/50 7/50 | Neoplastic Lesions |
| No | TR-285 | 569-61-9 | C.I. Basic Red 9 Monohydrochloride | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 1/50 1/50 13/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Forestomach | Clear Evidence | Clear Evidence | Squamous Cell Papilloma 0/50 0/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Male | Inhalation | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 0/50 2/50 4/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 1/50 3/50 3/50 8/50 OR CARCINOMA 1/50 2/50 0/50 1/50 COMBINED 2/50 5/50 3/50 9/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/50 5/50 8/50 10/50 OR CARCINOMA 0/50 0/50 2/50 2/50 COMBINED 2/50 5/50 10/50 12/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Male | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | (SINGLE SECTIONS) ADENOMA 0/50 1/49 1/50 3/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/50 2/49 3/50 9/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | (SINGLE SECTIONS) ADENOMA 0/49 0/50 0/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/49 0/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Male | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | (SINGLE SECTIONS) ADENOMA 0/50 1/50 1/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 1/50 7/50 6/50 7/50 OR CARCINOMA 0/50 2/50 0/50 1/50 COMBINED 1/50 9/50 6/50 8/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 17/50 19/49 11/50 16/50 OR CARCINOMA 4/50 11/49 14/50 19/50 COMBINED 20/50 26/49 20/50 30/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Lung | Clear Evidence | Equivocal Evidence | Alveolar/Bronchiolar Adenoma 1/49 0/50 0/50 3/50 | May Have Been Related |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | Alveolar/Bronchiolar Adenoma 2/50 16/49 29/50 26/50 or Alveolar/Bronchiolar Carcinoma 2/50 14/49 16/50 28/50 Combined 4/50 28/49 34/50 42/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | Alveolar/Bronchiolar Adenoma 8/50 18/50 22/50 28/50 or Alveolar/Bronchiolar Carcinoma 6/50 12/50 23/50 28/50 Combined 13/50 28/50 36/50 43/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | Alveolar/Bronchiolar Adenoma 2/50 0/50 3/49 3/50 or Alveolar/Bronchiolar Carcinoma 0/50 2/50 1/49 4/50 Combined 2/50 2/50 4/49 6/50 | Neoplastic Lesions |
| Yes | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | CARCINOMA 3/50 4/50 7/50 12/50 | Neoplastic Lesions |
| Yes | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 24/49 32/50 36/50 36/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | SARCOMA 0/50 4/50 8/50 3/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/49 2/50 2/50 7/50 OR SQUAMOUS CELL CARCINOMA 0/49 1/50 3/50 4/50 COMBINED 1/49 3/50 5/50 11/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Male | Inhalation | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/50 4/50 10/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 2/50 COMBINED 0/50 2/50 5/50 12/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/50 11/50 11/50 18/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 1/49 1/50 0/50 3/50 OR CARCINOMA 0/49 0/50 1/50 2/50 COMBINED 1/49 1/50 1/50 5/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Male | Inhalation | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/50 2/49 4/50 OR CARCINOMA 0/50 0/50 2/49 1/50 COMBINED 0/50 2/50 4/49 5/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Urinary Bladder | Clear Evidence | Equivocal Evidence | TRANSITIONAL EPITHELIUM CARCINOMA 0/49 0/50 0/50 2/50 | May Have Been Related |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Male | Inhalation | Urinary Bladder | Clear Evidence | Equivocal Evidence | TRANSITIONAL EPITHELIUM PAPILLOMA 0/50 0/50 0/50 1/49 OR CARCINOMA 0/50 0/50 1/50 0/49 | May Have Been Related |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Vascular System (Unspecified) | Clear Evidence | Clear Evidence | HEMANGIOMA 0/50 0/50 2/50 3/50 OR HEMANGIOSARCOMA 4/50 6/50 17/50 5/50 COMBINED 4/50 6/50 18/50 8/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Male | Inhalation | Vascular System (Unspecified) | Clear Evidence | Clear Evidence | HEMANGIOMA 0/50 1/50 2/50 2/50 OR HEMANGIOSARCOMA 3/50 13/50 22/50 19/50 COMBINED 3/50 14/50 23/50 21/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/50 0/50 0/50 3/50 | Neoplastic Lesions |
| No | TR-207 | 21739-91-3 | Cytembena | Mice | B6C3F1 | Female | Intraperitoneal Injection | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-207 | 21739-91-3 | Cytembena | Mice | B6C3F1 | Male | Intraperitoneal Injection | Unspecified | Negative | Not applicable | Not applicable | |
| Yes | TR-207 | 21739-91-3 | Cytembena | Rats | F344/N | Female | Intraperitoneal Injection | Mammary Gland | Positive | Positive | FIBROADENOMA 13/49 22/50 36/50 | Neoplastic Lesions |
| No | TR-207 | 21739-91-3 | Cytembena | Rats | F344/N | Male | Intraperitoneal Injection | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | MESOTHELIOMA 0/50 37/50 36/50 | Neoplastic Lesions |
| No | TR-545 | 446-72-0 | Endocrine disruptor (Genistein) | Rats | Sprague Dawley | Male | Dosed-Feed | Unspecified | No Evidence | Not applicable | Not applicable | |
| Yes | TR-545 | 446-72-0 | Endocrine disruptor (Genistein) | Rats | Sprague Dawley | Female | Dosed-Feed | Mammary Gland | Some Evidence | Equivocal Evidence | ADENOMA OR ADENOCARCINOMA 7/53 8/49 11/50 13/50 | May Have Been Related |
| Yes | TR-545 | 446-72-0 | Endocrine disruptor (Genistein) | Rats | Sprague Dawley | Female | Dosed-Feed | Mammary Gland | Some Evidence | Some Evidence | ADENOMA OR ADENOCARCINOMA 9/54 4/50 8/50 16/49 | Neoplastic Lesions |
| No | TR-545 | 446-72-0 | Endocrine disruptor (Genistein) | Rats | Sprague Dawley | Female | Dosed-Feed | Pituitary Gland | Some Evidence | Some Evidence | ADENOMA OR CARCINOMA 38/54 32/49 40/50 44/50 | Neoplastic Lesions |
| No | TR-545 | 446-72-0 | Endocrine disruptor (Genistein) | Rats | Sprague Dawley | Female | Dosed-Feed | Pituitary Gland | Some Evidence | Some Evidence | ADENOMA OR CARCINOMA 38/54 40/50 34/50 46/49 | Neoplastic Lesions |
| No | TR-510 | 64-17-5 | Ethanol | Mice | MV | Female | Dosed-Water | Unspecified | Inadequate Study | Not applicable | Not applicable | |
| No | TR-510 | 64-17-5 | Ethanol | Mice | MV | Male | Dosed-Water | Unspecified | Inadequate Study | Not applicable | Not applicable | |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | CYSTADENOMA 1/46 6/46 8/47 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | CYSTADENOMA 1/43 9/44 8/42 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 9/49 6/48 22/49 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 2/49 4/48 17/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/49 1/48 7/49 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 5/50 11/50 11/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 6/50 10/50 16/50 | Neoplastic Lesions |
| Yes | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 1/49 6/48 4/49; ADENOSQUAMOUS CARCINOMA 0/49 2/48 2/49 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/49 1/47 5/49 | Neoplastic Lesions |
| No | TR-356 | 54-31-9 | Furosemide | Rats | F344/N | Female | Dosed-Feed | Unspecified | No Evidence | Not applicable | Not applicable | |
| No | TR-356 | 54-31-9 | Furosemide | Rats | F344/N | Male | Dosed-Feed | Brain | Equivocal Evidence | Equivocal Evidence | MENINGIOMA 0/50 3/50 0/50 | Neoplastic Lesions |
| No | TR-356 | 54-31-9 | Furosemide | Rats | F344/N | Male | Dosed-Feed | Kidney Tubular Cell | Equivocal Evidence | Equivocal Evidence | ADENOMA 1/50 3/50 1/50 OR CARCINOMA 0/50 1/50 1/50 COMBINED 1/50 4/50 2/50 | Neoplastic Lesions |
| Yes | TR-356 | 54-31-9 | Furosemide | Mice | B6C3F1 | Female | Dosed-Feed | Mammary Gland | Some Evidence | Some Evidence | ADENOCARCINOMA 0/50 2/50 5/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | All Organs | Clear Evidence | Equivocal Evidence | Mononuclear Cell Leukemia 21/48 26/48 27/48 27/47 31/48 | May Have Been Related |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | All Organs | Clear Evidence | Clear Evidence | Mononuclear Cell Leukemia 14/48 11/48 21/48 19/48 27/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | carcinoma 4/48 6/48 7/48 11/48 14/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Epididymis | Clear Evidence | Clear Evidence | malignant mesothelioma 0/48 1/45 3/48 10/47 17/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Epididymis or Testis | Clear Evidence | Clear Evidence | malignant mesothelioma 0/48 1/48 3/48 10/47 17/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 1/45 1/45 1/47 5/45 9/44 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 0/47 2/45 3/48 2/45 10/41 squamous cell carcinoma 0/47 0/45 0/48 0/45 2/41 squamous cell papilloma or carcinoma 0/47 2/45 3/48 2/45 12/41 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 0/48 1/48 0/48 0/47 3/46 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 2/45 19/47 20/47 24/46 40/46 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 3/47 17/47 23/47 32/46 42/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | malignant schwannoma 2/48 3/48 3/48 7/47 8/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 3/46 5/48 3/47 7/47 9/44 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 0/47 7/46 7/47 13/47 17/47 | Neoplastic Lesions |
| Yes | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | adenoacanthoma 0/45 0/48 0/47 1/47 8/45 adenocarcinoma 1/45 1/48 2/47 9/47 11/45 adenoacanthoma or adenocarcinoma 1/45 1/48 2/47 9/47 18/45 | Neoplastic Lesions |
| Yes | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | fibroadenoma 16/48 26/48 35/48 33/48 36/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa or tongue: squamous cell papilloma or carcinoma 1/48 2/48 2/48 2/48 7/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Tongue: squamous cell papilloma 0/48 1/48 0/48 1/48 0/48 squamous cell carcinoma 0/48 0/48 0/48 0/48 1/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa: squamous cell papilloma 1/48 1/48 2/48 0/48 4/48 squamous cell carcinoma 0/48 0/48 0/48 1/48 2/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Tongue: squamous cell papilloma 0/48 1/48 0/48 1/47 4/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa: squamous cell papilloma 1/48 1/48 0/48 2/47 3/48 squamous cell carcinoma 1/48 0/48 1/48 1/47 0/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa or tongue: squamous cell papilloma or carcinoma 2/48 2/48 2/48 3/47 7/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Ovary | Clear Evidence | Equivocal Evidence | granulosa cell tumor – benign or malignant 0/45 0/47 0/47 3/46 3/44 | May Have Been Related |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | fibrosarcoma 0/45 1/48 2/47 2/47 9/45 sarcoma 0/45 0/48 1/47 3/47 3/45 fibrosarcoma or sarcoma 0/45 1/48 3/47 5/47 12/45 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | squamous cell papilloma 0/47 1/48 2/47 1/47 8/46 squamous cell carcinoma 0/47 0/48 0/47 0/47 2/46 squamous cell papilloma or carcinoma 0/47 1/48 2/47 1/47 9/46 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Testis | Clear Evidence | Clear Evidence | malignant mesothelioma 0/48 1/47 3/48 6/47 13/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 0/48 3/48 3/46 1/46 5/47 follicular cell carcinoma 0/48 0/48 2/46 3/46 3/47 follicular cell adenoma or carcinoma 0/48 3/48 5/46 4/46 8/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 2/47 1/42 3/48 3/47 8/46 follicular cell carcinoma 0/47 2/42 3/48 1/47 5/46 follicular cell adenoma or carcinoma 2/47 3/42 6/48 4/47 13/46 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Brain | Clear Evidence | Clear Evidence | GLIOMA 0/50 4/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Brain | Clear Evidence | Clear Evidence | GLIOMA 0/50 5/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Epididymis | Clear Evidence | Equivocal Evidence | SARCOMA 0/50 0/50 2/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/50 9/50 OR SQUAMOUS CELL CARCINOMA 1/50 0/50 1/50 COMBINED 1/50 2/50 10/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 4/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 4/50 11/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 1/50 1/50 2/50 COMBINED 1/50 2/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Glandular Stomach | Clear Evidence | Equivocal Evidence | FIBROSARCOMA 0/50 0/50 2/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LEUKEMIA 13/50 14/50 20/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 1/50 3/50 COMBINED 0/50 1/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 18/50 16/50 30/50 OR CARCINOMA 10/50 17/50 8/50 COMBINED 24/50 31/50 35/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 6/50 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/50 5/50 14/50 COMBINED 13/50 11/50 21/50 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 3/50 8/50 7/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 3/50 34/50 39/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 6/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 1/50 3/50 7/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/49 OR CARCINOMA 0/50 0/50 3/49 COMBINED 0/50 1/50 3/49 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/50 2/50 OR CARCINOMA 1/50 2/50 5/50 COMBINED 1/50 4/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Urinary Bladder | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 1/50 1/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Clear Evidence | Clear Evidence | CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 1/50 3/50 6/50 | Neoplastic Lesions |
| No | TR-092 | 122-66-7 | Hydrazobenzene | Mice | B6C3F1 | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-092 | 122-66-7 | Hydrazobenzene | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-092 | 122-66-7 | Hydrazobenzene | Rats | F344/N | Female | Dosed-Feed | Liver | Positive | Positive | (NEOPLASTIC NODULE) | Neoplastic Lesions |
| No | TR-092 | 122-66-7 | Hydrazobenzene | Rats | F344/N | Male | Dosed-Feed | Liver | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| Yes | TR-092 | 122-66-7 | Hydrazobenzene | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-092 | 122-66-7 | Hydrazobenzene | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Positive | Positive | (SQUAMOUS CELL PAPILLOMA OR CARCINOMA) | Neoplastic Lesions |
| No | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Female | Inhalation | Adrenal Gland Medulla | Clear Evidence | Clear Evidence | BENIGN PHEOCHROMOCYTOMA 2/50 6/48 2/50 9/49 | Neoplastic Lesions |
| No | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Male | Inhalation | Adrenal Gland Medulla | Clear Evidence | Clear Evidence | BENIGN PHEOCHROMOCYTOMA 10/50 22/50 16/49 23/50 BENIGN OR MALIGNANT PHEOCHROMOCYTOMA 10/50 26/50 18/49 24/50 | Neoplastic Lesions |
| No | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Female | Inhalation | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 14/50 21/50 14/50 24/50 | May Have Been Related |
| No | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Male | Inhalation | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 16/50 23/50 29/50 25/50 | May Have Been Related |
| No | TR-499 | 22398-80-7 | Indium phosphide | Mice | B6C3F1 | Male | Inhalation | Intestines (Large) | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 1/50 5/50 3/50; ADEMONA OR CARCINOMA 1/50 2/50 6/50 3/50 | May Have Been Related |
| No | TR-499 | 22398-80-7 | Indium phosphide | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 12/50 14/50 18/50 14/50; CARCINOMA 6/50 17/50 8/50 10/50; COMBINED 18/50 28/50 24/50 23/50 | Neoplastic Lesions |
| No | TR-499 | 22398-80-7 | Indium phosphide | Mice | B6C3F1 | Male | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 17/50 24/50 23/50 32/50; CARCINOMA 11/50 22/50 23/50 16/50; COMBINED 26/50 40/50 37/50 39/50 | Neoplastic Lesions |
| No | TR-499 | 22398-80-7 | Indium phosphide | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADEMONA 3/50 6/50 10/50 7/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 6/50 5/50 7/50; COMBINED 4/50 11/50 15/50 14/50 | Neoplastic Lesions |
| No | TR-499 | 22398-80-7 | Indium phosphide | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR CARCINOMA 6/50 15/50 22/50 13/50 | Neoplastic Lesions |
| No | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADEMONA 0/50 7/50 5/50 19/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 3/50 1/50 11/50; COMBINED 1/50 10/50 6/50 26/50 | Neoplastic Lesions |
| No | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADEMONA 6/50 13/50 27/50 30/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 10/50 8/50 16/50; COMBINED 7/50 22/50 30/50 35/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 0/50 4/50 | Neoplastic Lesions |
| Yes | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Female | Inhalation | Mammary Gland | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 8/50 3/50 2/50 | May Have Been Related |
| No | TR-499 | 22398-80-7 | Indium phosphide | Rats | F344/N | Male | Inhalation | Skin | Clear Evidence | Equivocal Evidence | FIBROMA 1/50 4/50 7/50 3/50; FIBROMA OR FIBROSARCOMA 2/50 4/50 8/50 4/50 | May Have Been Related |
| No | TR-032 | 3778-73-2 | Isophosphamide | Mice | B6C3F1 | Male | Intraperitoneal Injection | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-032 | 3778-73-2 | Isophosphamide | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-032 | 3778-73-2 | Isophosphamide | Mice | B6C3F1 | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| Yes | TR-032 | 3778-73-2 | Isophosphamide | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Mammary Gland | Positive | Positive | (FIBROADENOMA) | Neoplastic Lesions |
| No | TR-032 | 3778-73-2 | Isophosphamide | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Uterus/Cervix | Positive | Positive | (LEIOMYOSARCOMA) | Neoplastic Lesions |
| No | TR-486 | 78-79-5 | Isoprene | Rats | F344/N | Female | Inhalation | Brain | Some Evidence | Equivocal Evidence | ASTROCYTOMA 0/50 0/50 1/50 0/50, GLIOMA 0/50 0/50 0/50 1/50, MEDULOBLASTOMA 0/50 0/50 0/50 1/50, MENINGEAL GRANULAR CELL TUMOR 0/50 1/50 0/50 1/50, MENINGEAL SARCOMA 0/50 1/50 0/50 1/50 | May Have Been Related |
| No | TR-486 | 78-79-5 | Isoprene | Rats | F344/N | Male | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | (SINGLE SECTION) ADENOMA 0/50 2/50 2/50 6/50 (SINGLE AND STEP SECTION) ADENOMA 2/50 4/50 8/50 15/50 | Neoplastic Lesions |
| Yes | TR-486 | 78-79-5 | Isoprene | Rats | F344/N | Male | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 2/50 4/50 6/50 21/50 FIBROADENOMA OR CARCINOMA COMBINED 2/50 5/50 7/50 21/50 | Neoplastic Lesions |
| Yes | TR-486 | 78-79-5 | Isoprene | Rats | F344/N | Female | Inhalation | Mammary Gland | Some Evidence | Some Evidence | FIBROADENOMA 19/50 35/50 32/50 32/50 MULTIPLE FIBROADENOMA 7/50 12/50 19/50 17/50 | Neoplastic Lesions |
| No | TR-486 | 78-79-5 | Isoprene | Rats | F344/N | Male | Inhalation | Testis | Clear Evidence | Clear Evidence | ADENOMA 33/50 37/50 44/50 48/50 | Neoplastic Lesions |
| No | TR-306 | 75-09-2 | Methylene chloride | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 2/50 6/48 22/48 OR CARCINOMA 1/50 11/48 32/48 COMBINED 3/50 16/48 40/48 | Neoplastic Lesions |
| No | TR-306 | 75-09-2 | Methylene chloride | Mice | B6C3F1 | Male | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 10/50 14/49 14/49 OR CARCINOMA 13/50 15/49 26/49 COMBINED 22/50 24/49 33/49 | Neoplastic Lesions |
| No | TR-306 | 75-09-2 | Methylene chloride | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 2/50 23/48 28/48; ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 13/48 29/48 | Neoplastic Lesions |
| No | TR-306 | 75-09-2 | Methylene chloride | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 3/50 19/50 24/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 10/50 28/50 | Neoplastic Lesions |
| Yes | TR-306 | 75-09-2 | Methylene chloride | Rats | F344/N | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/50 0/50 1/50 OR FIBROADENOMA 5/50 11/50 13/50 22/50 COMBINED 5/50 11/50 13/50 23/50 | Neoplastic Lesions |
| Yes | TR-306 | 75-09-2 | Methylene chloride | Rats | F344/N | Male | Inhalation | Mammary Gland | Some Evidence | Some Evidence | ADENOMA 0/50 0/50 0/50 1/50 OR FIBROADENOMA 0/50 0/50 2/50 4/50 COMBINED 0/50 0/50 2/50 5/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Female | Gavage | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 1/50 3/50 | May Have Been Related |
| No | TR-491 | 93-15-2 | Methyleugenol | Mice | B6C3F1 | Male | Gavage | Glandular Stomach | Clear Evidence | Clear Evidence | MALIGNANT NEUROENDOCRINE TUMOR 0/49 0/48 0/49 2/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Female | Gavage | Glandular Stomach | Clear Evidence | Clear Evidence | BENIGN NEUROENDOCRINE TUMOR 0/50 0/50 13/50 9/50 5/50 OR MALIGNANT NEUROENDOCRINE TUMOR 0/50 1/50 12/50 26/50 36/50 COMBINED 0/50 1/50 25/50 34/50 41/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Glandular Stomach | Clear Evidence | Clear Evidence | BENIGN NEUROENDOCRINE TUMOR 1/50 0/50 0/50 3/50 2/50 OR MALIGNANT NEURENDOCRINE TUMOR 0/50 0/50 0/50 4/50 2/50 COMBINED 1/50 0/50 0/50 7/50 4/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA (STANDARD AND EXTENDED COMBINED) 4/50 6/50 17/50 13/50 20/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Mice | B6C3F1 | Female | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 20/50 48/50 46/49 41/50 OR CARCINOMA 7/50 37/50 47/49 47/50 COMBINED 25/50 50/50 49/49 49/50; HEPATOBLASTOMA 0/50 6/50 11/49 15/50; HEPATOCHOLANGIOCARCINOMA 0/50 0/50 0/50 2/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 26/49 43/50 38/50 39/50 CARCINOMA 10/49 20/50 19/50 9/50 COMBINED 31/49 47/50 46/50 40/50; HEPATOBLASTOMA 0/49 0/50 1/50 3/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Female | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 1/50 8/50 11/49 33/49 43/50 OR CARCINOMA 0/50 0/50 4/49 8/49 22/50 COMBINED 1/50 8/50 14/49 34/49 43/50; HEPATOCHOLANGIOMA 0/50 0/50 0/49 0/49 8/50 OR HEPATOCHOLANGIOCARCINOMA 0/50 0/50 0/49 3/49 9/50 COMBINED 0/50 0/50 0/49 3/49 17/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 5/50 12/50 23/50 38/50 32/50 OR CARCINOMA 2/50 3/50 14/50 25/50 36/50 COMBINED 7/50 14/50 28/50 43/50 45/50; HEPATOCHOLANGIOMA 0/50 0/50 0/50 1/50 6/50 OR HEPATOCHOLANGIOCARCINOMA 0/50 0/50 1/50 1/50 7/50 COMBINED 0/50 0/50 1/50 2/50 13/50 | Neoplastic Lesions |
| Yes | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 5/50 5/50 15/50 13/50 6/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 1/50 3/50 5/50 12/50 5/50 | Neoplastic Lesions |
| No | TR-491 | 93-15-2 | Methyleugenol | Rats | F344/N | Male | Gavage | Skin | Clear Evidence | Clear Evidence | FIBROMA 1/50 9/50 8/50 5/50 4/50 OR FIBROMA OR FIBROSARCOMA 1/50 12/50 8/50 8/50 4/50 | Neoplastic Lesions |
| No | TR-146 | 139-94-6 | Nithiazide | Rats | F344/N | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-146 | 139-94-6 | Nithiazide | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Equivocal Evidence | Equivocal | (ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| No | TR-146 | 139-94-6 | Nithiazide | Mice | B6C3F1 | Male | Dosed-Feed | Liver | Positive | Positive | (ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| Yes | TR-146 | 139-94-6 | Nithiazide | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (FIBROADENOMA OR CYSTADENOMA) | Neoplastic Lesions |
| No | TR-146 | 139-94-6 | Nithiazide | Rats | F344/N | Female | Dosed-Feed | Skin | Positive | Positive | (FIBROADENOMA OR CYSTADENOMA) | Neoplastic Lesions |
| No | TR-337 | 59-87-0 | Nitrofurazone | Mice | B6C3F1 | Male | Dosed-Feed | Unspecified | No Evidence | Not applicable | Not applicable | |
| Yes | TR-337 | 59-87-0 | Nitrofurazone | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 8/49 36/50 36/50 | Neoplastic Lesions |
| No | TR-337 | 59-87-0 | Nitrofurazone | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Equivocal Evidence | Equivocal Evidence | MESOTHELIOMA 0/50 7/50 2/50 | Neoplastic Lesions |
| No | TR-337 | 59-87-0 | Nitrofurazone | Mice | B6C3F1 | Female | Dosed-Feed | Ovary | Clear Evidence | Clear Evidence | GRANULOSA CELL TUMOR 1/47 4/50 9/50; BENIGN MIXED TUMORS 0/47 17/50 20/50 | Neoplastic Lesions |
| No | TR-337 | 59-87-0 | Nitrofurazone | Rats | F344/N | Male | Dosed-Feed | Preputial Gland | Equivocal Evidence | Equivocal Evidence | ADENOMA 8/50 8/50 2/50 OR CARCINOMA 1/50 8/50 5/50 COMBINED 9/50 16/50 7/50 | Neoplastic Lesions |
| No | TR-337 | 59-87-0 | Nitrofurazone | Rats | F344/N | Male | Dosed-Feed | Skin | Equivocal Evidence | Equivocal Evidence | SEBACEOUS GLAND ADENOMA 0/50 0/50 4/50; TRICHOEPITHELIOMA 0/50 0/50 1/50 | Neoplastic Lesions |
| No | TR-461 | 75-52-5 | Nitromethane | Rats | F344/N | Male | Inhalation | Unspecified | No Evidence | Not applicable | Not applicable | |
| No | TR-461 | 75-52-5 | Nitromethane | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 5/50 7/50 16/50 19/50 OR CARCINOMA 1/50 2/50 4/50 3/50 COMBINED 6/50 9/50 20/50 21/50 | Neoplastic Lesions |
| No | TR-461 | 75-52-5 | Nitromethane | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 9/50 10/50 19/50 32/50 OR CARCINOMA 1/50 1/50 6/50 5/50 COMBINED 10/50 11/50 25/50 37/50 | Neoplastic Lesions |
| No | TR-461 | 75-52-5 | Nitromethane | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 14/50 25/50 17/50 35/50 OR CARCINOMA 10/50 14/50 8/50 12/50 COMBINED 19/50 34/50 22/50 40/50 | Neoplastic Lesions |
| No | TR-461 | 75-52-5 | Nitromethane | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 3/50 3/50 2/50 9/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 3/50 5/50 3/50 COMBINED 3/50 6/50 6/50 12/50 | Neoplastic Lesions |
| No | TR-461 | 75-52-5 | Nitromethane | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR ADENOMA 11/50 10/50 9/50 12/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 3/50 3/50 11/50 COMBINED 13/50 13/50 12/50 20/50 | Neoplastic Lesions |
| Yes | TR-461 | 75-52-5 | Nitromethane | Rats | F344/N | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 19/50 21/50 33/50 36/50 OR CARCINOMA 2/50 7/50 1/50 11/50 COMBINED 9/50 25/50 34/50 39/50 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Mice | B6C3F1 | Female | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/60 2/60 3/60 50/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Mice | B6C3F1 | Male | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 4/60 17/60 55/60 60/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Mice | B6C3F1 | Female | Dosed-Feed | Intestines (Large) | Clear Evidence | Clear Evidence | (CECUM) CARCINOMA 0/60 1/60 4/60 3/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Mice | B6C3F1 | Male | Dosed-Feed | Intestines (Large) | Clear Evidence | Clear Evidence | (CECUM) CARCINOMA 0/60 12/60 9/60 0/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Female | Dosed-Feed | Liver | Clear Evidence | Equivocal Evidence | ADENOMA 1/60 0/59 1/60 6/60 | May Have Been Related |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | ADENOMA 7/60 5/59 19/59 29/60 CARCINOMA 2/60 4/59 6/59 16/60 COMBINED 9/60 9/59 24/59 39/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Liver | Clear Evidence | Clear Evidence | ADENOMA 2/60 3/60 3/60 7/60 3/60 4/60 ADENOMA OR CARCINOMA 3/60 3/60 3/60 8/60 3/60 6/60 CHOLANGIOCARCINOMA 0/60 0/60 0/60 0/60 0/60 3/60 HEPATOCHOLANGIOCARCINOMA 0/60 1/60 0/60 1/60 0/60 0/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 5/60 1/60 2/60 3/60 8/60 OR ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 2/60 5/60 1/60 2/60 3/60 11/60 | Neoplastic Lesions |
| Yes | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 23/60 47/60 52/60 56/60 | Neoplastic Lesions |
| Yes | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 0/60 7/60 10/60 2/60 13/60 20/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MALIGNANT MESOTHELIOMA 2/60 20/60 29/60 44/60 44/60 54/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Female | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | (SUBCUTANEOUS) FIBROMA 3/60 3/60 18/60 20/60 FIBROMA OR FIBROSARCOMA 3/60 3/60 21/60 22/60 | Neoplastic Lesions |
| No | TR-504 | 88-72-2 | o-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | (SUBCUTANEOUS) LIPOMA 0/60 4/60 13/60 13/60 10/60 12/60 FIBROMA 5/60 46/60 52/60 59/60 45/60 52/60 FIBROSARCOMA 0/60 7/60 17/60 20/60 8/60 12/60 COMBINED 5/60 47/60 55/60 59/60 47/60 53/60 | Neoplastic Lesions |
| No | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | (ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| Yes | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (ADENOMA OR FIBROADENOMA) | Neoplastic Lesions |
| No | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Positive | Positive | MESOTHELIOMA | Neoplastic Lesions |
| No | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Rats | F344/N | Female | Dosed-Feed | Spleen | Positive | Positive | (SARCOMA) | Neoplastic Lesions |
| No | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Rats | F344/N | Male | Dosed-Feed | Spleen | Positive | Positive | (SARCOMA) | Neoplastic Lesions |
| No | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Rats | F344/N | Male | Dosed-Feed | Subcutaneous Tissue | Positive | Positive | (FIBROMA) | Neoplastic Lesions |
| No | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Rats | F344/N | Female | Dosed-Feed | Urinary Bladder | Positive | Positive | (TRANSITIONAL CELL CARCINOMA) | Neoplastic Lesions |
| No | TR-153 | 636-21-5 | o-Toluidine hydrochloride | Mice | B6C3F1 | Male | Dosed-Feed | Vascular System (Unspecified) | Positive | Positive | HEMANGIOSARCOMA | Neoplastic Lesions |
| No | TR-358 | 303-47-9 | Ochratoxin A | Rats | F344/N | Female | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/51 1/50 5/50 OR CARCINOMA 0/50 0/51 1/50 3/50 | Neoplastic Lesions |
| No | TR-358 | 303-47-9 | Ochratoxin A | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 1/50 1/51 6/51 10/50 OR CARCINOMA 0/50 0/51 16/51 30/50 | Neoplastic Lesions |
| Yes | TR-358 | 303-47-9 | Ochratoxin A | Rats | F344/N | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 17/50 23/51 22/50 28/50 | Neoplastic Lesions |
| No | TR-060 | 3546-10-9 | Phenesterin | Rats | Sprague Dawley | Male | Gavage | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Female | Gavage | Heart | Positive | Positive | (SARCOMA) | Neoplastic Lesions |
| No | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Male | Gavage | Heart | Positive | Positive | (SARCOMA) | Neoplastic Lesions |
| No | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Female | Gavage | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| No | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Male | Gavage | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| No | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Female | Gavage | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR CARCINOMA) | Neoplastic Lesions |
| No | TR-060 | 3546-10-9 | Phenesterin | Mice | B6C3F1 | Male | Gavage | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR CARCINOMA) | Neoplastic Lesions |
| Yes | TR-060 | 3546-10-9 | Phenesterin | Rats | Sprague Dawley | Female | Gavage | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Brain | Positive | Positive | (NEUROBLASTOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Male | Intraperitoneal Injection | Brain | Positive | Positive | (NEUROBLASTOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Brain | Positive | Positive | (NEUROBLASTOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Brain | Positive | Positive | (ADENOCARCINOMA, NEUROBLASTOMA, CARCINOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Male | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Male | Intraperitoneal Injection | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA) | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Uterus/Cervix | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-193 | 50-55-5 | Reserpine | Rats | F344/N | Female | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-193 | 50-55-5 | Reserpine | Rats | F344/N | Male | Dosed-Feed | Adrenal Gland Medulla | Positive | Positive | PHEOCHROMOCYTOMA | Neoplastic Lesions |
| Yes | TR-193 | 50-55-5 | Reserpine | Mice | B6C3F1 | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (FIBROADENOMA, ADENOCARCINOMA, ADENOSQUAMOUS CARCINOMA) | Neoplastic Lesions |
| No | TR-193 | 50-55-5 | Reserpine | Mice | B6C3F1 | Male | Dosed-Feed | Seminal Vesicle | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-115 | 95-06-7 | Sulfallate | Rats | Osborne Mendel | Male | Dosed-Feed | Forestomach | Positive | Positive | (SQUAMOUS CELL PAPILLOMA OR CARCINOMA) | Neoplastic Lesions |
| No | TR-115 | 95-06-7 | Sulfallate | Mice | B6C3F1 | Male | Dosed-Feed | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA, CARCINOMA) | Neoplastic Lesions |
| Yes | TR-115 | 95-06-7 | Sulfallate | Mice | B6C3F1 | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-115 | 95-06-7 | Sulfallate | Rats | Osborne Mendel | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/46 2/47 3/44 5/45 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/48 10/48 8/48 21/48 CARCINOMA 0/48 1/48 11/48 11/48 COMBINED 3/48 11/48 19/48 30/48 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/47 11/47 25/47 28/47 CARCINOMA 0/47 1/47 7/47 16/47 COMBINED 3/47 12/47 30/47 38/47 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/48 1/47 5/48 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/47 1/47 7/47 ADENOMA 5/48 10/47 19/47 18/47 ADENOMA OR CARCINOMA 5/48 11/47 20/47 19/47 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 1/46 2/47 5/46 13/44 ADENOMA 7/46 13/47 17/46 17/44 ADENOMA OR CARCINOMA 12/46 18/47 24/46 23/44 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 4/48 6/48 17/48 29/47 ALVEOLAR/BRONCHIOLAR CARCINOMA 2/48 4/48 13/48 19/47 COMBINED 6/48 8/48 28/48 39/47 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 4/48 17/48 22/47 34/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 1/48 1/48 9/47 9/48 COMBINED 5/48 18/48 29/47 37/48 | Neoplastic Lesions |
| Yes | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | ADENOACANTHOMA 0/47 1/46 1/46 11/48 ADENOCARCINOMA 4/47 3/46 3/46 11/48 COMBINED 4/47 4/46 4/46 22/48 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Ovary | Clear Evidence | Clear Evidence | BENIGN GRANULOSA CELL TUMOR 0/48 0/46 2/46 3/39 MALIGNANT GRANULOSA CELL TUMOR 0/48 0/46 0/46 3/39 COMBINED 0/48 0/46 2/46 5/39 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/48 0/46 2/48 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/47, 1/48, 5/47, 8/48) | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Spleen | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/45 1/47 4/46 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Uterus/Cervix | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/47 0/48 2/46 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ADENOMA 4/48 7/48 6/46 20/46 CARCINOMA 1/48 11/48 7/46 10/46 COMBINED 5/48 18/48 13/46 29/46 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ADENOMA 2/47 3/47 9/46 19/47 CARCINOMA 1/47 3/47 6/46 16/47 COMBINED 3/47 5/47 15/46 35/47 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ADENOMA 5/47 12/48 15/48 26/45 CARCINOMA 0/47 2/48 2/48 10/45 COMBINED 5/47 14/48 17/48 35/45 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ADENOMA 6/48 14/48 21/47 27/48 CARCINOMA 0/48 0/48 1/47 16/48 COMBINED 6/48 14/48 21/47 38/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/47 0/48 0/48 6/47 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/47 0/48 3/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/48 0/48 2/47 4/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/47 0/48 1/48 4/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/48 0/47 0/48 6/48 ADENOMA 3/48 6/47 16/48 16/48 ADENOMA OR CARCINOMA 3/48 7/47 16/48 17/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 1/47 2/47 0/47 7/46 ADENOMA 6/47 5/47 15/47 23/46 ADENOMA OR CARCINOMA 7/47 5/47 16/47 23/46 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 2/48 2/46 4/48 13/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 3/47 4/48 3/46 11/48 ADENOMA 12/47 15/48 16/46 24/48 ADENOMA OR CARCINOMA 16/47 19/48 17/46 24/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADENOMA 5/47 10/47 16/48 28/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 0/47 2/47 6/48 23/48 COMBINED 5/47 11/47 21/48 38/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADEMONA 5/48 10/48 18/48 30/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 1/48 7/48 9/48 23/48 COMBINED 5/48 17/48 24/48 37/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADEMONA 6/48 8/48 9/48 33/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 5/48 4/48 5/48 17/48 COMBINED 11/48 11/48 14/48 40/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADENOMA 10/48 16/48 19/47 35/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 2/48 3/48 8/47 24/48 COMBINED 11/48 19/48 24/47 43/48 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ADENOACANTHOMA 0/47 0/45 2/48 3/47 ADENOCARCINOMA 4/47 3/45 11/48 14/47 COMBINED 4/47 3/45 12/48 16/47 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ADENOACANTHOMA 0/47 0/48 1/48 9/45 ADENOCARCINOMA 3/47 4/48 6/48 15/45 COMBINED 3/47 4/48 7/48 23/45 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Ovary | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) BENIGN GRANULOSA CELL TUMOR 0/46 0/47 5/46 3/45 BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 0/46 0/47 6/46 3/45 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/47 0/48 2/47 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/48, 2/47, 0/48, 7/48) | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/48, 1/48, 4/46, 7/47) | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Spleen | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/46 0/46 3/46 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Spleen | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/46 0/46 1/46 3/46 | Neoplastic Lesions |
| No | TR-549 | 5589-96-8 | Water disinfection byproducts (Bromochloroacetic acid) | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | Adenoma 0/50 0/50 3/50 7/50 | Neoplastic Lesions |
| No | TR-549 | 5589-96-8 | Water disinfection byproducts (Bromochloroacetic acid) | Rats | F344/N | Male | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | Adenoma 0/50 2/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-549 | 5589-96-8 | Water disinfection byproducts (Bromochloroacetic acid) | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Equivocal Evidence | Adenoma 0/50 0/50 0/50 3/50 | May Have Been Related |
| No | TR-549 | 5589-96-8 | Water disinfection byproducts (Bromochloroacetic acid) | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Equivocal Evidence | Adenoma 2/50 0/50 3/50 4/50 | May Have Been Related |
| No | TR-549 | 5589-96-8 | Water disinfection byproducts (Bromochloroacetic acid) | Mice | B6C3F1/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidenc |